Trial intelligence / Profile preview

ERICA trial: Eribulin followed by Capecitabine versus reverse sequence in HER2-negative metastatic breast cancer

2017-004652-35Phase 2Completed

Sponsor

Consorzio Oncotech

Start

Nov 2020

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules

Countries

1